Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Jill E Blind
Observed names:
Jill Blind,
Jill E. Blind
Institution:
Nationwide Children's Hospital
Observed institution:
Nationwide Children's Hospital
ORCID:
0000-0003-3450-2175
Observed ORCID:
0000-0003-3450-2175
OpenAlex ID:
A5040716791
Gene Replacement Therapy: A Primer for the Health-system Pharmacist
2019
·
John Petrich
, Dominic Marchese
, et al.
·
Journal of Pharmacy Practice
·
63
PDF
Clinical change 2 years from start of elexacaftor‐tezacaftor‐ivacaftor in severe cystic fibrosis
2023
·
Karen S. McCoy
, Jill Blind
, et al.
·
Pediatric Pulmonology
·
33
Viral-mediated gene therapy and genetically modified therapeutics: A primer on biosafety handling for the health-system pharmacist
2019
·
Jill E Blind
, E Nicole McLeod
, et al.
·
American Journal of Health-System Pharmacy
·
30
Biosafety Practices for In Vivo Viral-Mediated Gene Therapy in the Health Care Setting
2020
·
Jill E. Blind
, E. Nicole McLeod
, et al.
·
Applied Biosafety
·
17
Safeguards for Using Viral Vector Systems in Human Gene Therapy: A Resource for Biosafety Professionals Mitigating Risks in Health Care Settings
2020
·
Alex M. Brown
, Jill Blind
, et al.
·
Applied Biosafety
·
15
A call to action: Health-system pharmacists must stand up to meet the growing demand for cellular-based therapies
2023
·
Jill E Blind
, Diana N Nowicki
, et al.
·
American Journal of Health-System Pharmacy
·
10
Implementation and Patient Outcomes of a Pediatric COVID-19 Monoclonal Antibody Program
2022
·
Jill E Blind
, Matt Sapko
, et al.
·
Journal of the Pediatric Infectious Diseases Society
·
6
ASHP and ASHP Foundation Pharmacy Forecast 2026: Strategic Planning Guidance for Pharmacy Departments in Hospitals and Health Systems
2025
·
Joseph T DiPiro
, Rick Couldry
, et al.
·
American Journal of Health-System Pharmacy
·
4
PDF
From innovation to implementation: Health‐system pharmacy integration of cell and gene therapies
2026
·
Danielle Pennock
, Kelin Wheaton
, et al.
·
Transfusion
·
3
PDF
Same-Day Approach for Combined Intravitreal and Intracerebroventricular Enzyme Replacement Therapy to Prevent Retinal Disease Progression in Children With Neuronal Ceroid Lipofuscinosis Type 2
2025
·
David L. Rogers
, Jill E. Blind
, et al.
·
Pediatric Neurology
·
3
PDF
Biosafety Guidelines for Viral Vector-Based Gene Therapies: A Resource for Healthcare and Pharmacy Professionals
2025
·
Sumit Ghosh
, Jill Blind
, et al.
·
Applied Biosafety
·
3
A practical approach to assess the hazardous exposure potential of investigational drugs
2020
·
E Nicole McLeod
, Cambree J Fillis
, et al.
·
American Journal of Health-System Pharmacy
·
3
A comprehensive literature scoping review of infection prevention and control methods for viral-mediated gene therapies
2024
·
Jill E. Blind
, Sumit Ghosh
, et al.
·
Antimicrobial Stewardship & Healthcare Epidemiology
·
2
PDF
IDS pharmacists: Bridging the translational research gap for pharmacy practice
2024
·
Jill E. Blind
, Julie Leary
·
Journal of the American Pharmacists Association
·
1
PDF
Chapter 7: Novel Biological Therapies
2025
·
Jill E. Blind
, Kim McConnell
·
The American Pharmacists Association eBooks
Assessing the Readiness to Implement USP within theInvestigational Drug Service of a Pediatric Hospital
2018
·
Edward Yoo
, Nicole McLeod
, et al.
·
Research and reviews : journal of pharmacy and pharmaceutical sciences
Using Relative-Value Units (RVUs) to Distribute Workload and Justify Services in an Investigational Drug Service (IDS) Pharmacy
2015
·
Kasandra Chambers
, Jill E Blind
, et al.
·
DigitalCommons-Cedarville (Cedarville University)
Show more works
View as search
Works count:
17
Citation count:
193
H-index:
6
I10-index:
6
Year
Topic
Type